Terapevticheskii arkhivTerapevticheskii arkhivТерапевтический архив0040-36602309-5342LLC Obyedinennaya Redaktsiya31141Editorial articleПередовая статьяResearch ArticlePulmonary hypertension in rheumatic heart disease: current approaches to diagnosis and therapyЛегочная гипертония при ревматической болезни сердца: современные подходы к диагностике и терапииShostakN AШостакН АKlimenkoA AКлименкоА АNovikovI VНовиковИ ВDemidovaN AДемидоваН АAksenovaA VАксеноваА ВГБОУ ВПО "Российский национальный исследовательский медицинский университет", Москва150920122012849VOL 84, NO9 ()ТОМ 84, №9 (2012)899610042020Received:10042020Published:15092012Copyright ©; 2012, Consilium MedicumCopyright ©; 2012, ООО "Консилиум Медикум"2012Consilium MedicumООО "Консилиум Медикум"https://creativecommons.org/licenses/by-nc-sa/4.0https://ter-arkhiv.ru/0040-3660/article/view/31141

Pulmonary hypertension is a complex multidisciplinary problem in modern medicine. This review discusses its clinical and pathophysiological type associated with rheumatic heart disease. Current approaches to the pathogenesis and diagnosis of the disease are reflected; basic approaches to its treatment are discussed in terms of current clinical guidelines and new scientific achievements.

Аннотация. В современной медицине легочная гипертония является комплексной мультидисциплинарной проблемой. В настоящем обзоре обсуждается клинико-патофизиологический вариант заболевания, ассоциированный с ревматической болезнью сердца. Отражены современные взгляды на патогенез и диагностику заболевания, приведены основные подходы к лечению с учетом действующих клинических рекомендаций и новых научных достижений.

pulmonary hypertensionrheumatic heart diseaseendothelial dysfunctionлегочная гипертонияревматическая болезнь сердцадисфункция эндотелияMcLaughlin V.V., Archer S.L., Badesch D.B. et al.; ACCF/AHA. ACCF/AHA 2009 expert consensus document on pulmonary hypertension: a report of the American College of Cardiology Foundation Task Force on Expert Consensus Documents and the American Heart Association: developed in collaboration with the American College of Chest Physicians, American Thoracic Society, Inc., and the Pulmonary Hypertension Association. Circulation 2009; 119: 2250-2294.Galiè N., Hoeper M.M., Humbert M. et al.; ESC Committee for Practice Guidelines (CPG). Guidelines for the diagnosis and treatment of pulmonary hypertension: the Task Force for the Diagnosis and Treatment of Pulmonary Hypertension of the European Society of Cardiology (ESC) and the European Respiratory Society (ERS), endorsed by the International Society of Heart and Lung Transplantation (ISHLT). Eur Heart J 2009; 30: 2493-2537.Фоломеева О.М., Галушко Е.А., Эрдес Ш.Ф. Распространенность ревматических заболеваний в популяциях взрослого населения России и США. Науч-практ ревматол 2008; 4: 4-13.Заболеваемость населения России в 2006 году. Статистические материалы. Министерство здравоохранения и социального развития Российской Федерации. М 2007.Rubin L.J. Diagnosis and Management of Pulmonary Arterial Hypertension: ACCP Evidence Based Clinical Practice Guidelines. Chest 2004; 126: 7-10.Miyamoto S., Nagaya N., Satoh T. et al. Clinical correlates and prognostic significance of six-mint walk test in patients with primary pulmonary hypertension. Comparison with cardiopulmonary exercise testing. Am J Resrir Crit Care Med 2000; 161: 487-492.Kapoor A., Kumar S., Shukla A. et al. Determinants of left atrial pressure in rheumatic mitral stenosis: role of left atrial compliance and "atrial stiffness". Indeian Heart J 2004; 56: 27-31.Schwammenthal E., Vered Z., Agranat O. et al. Impact of Atrioventricular Compliance on Pulmonary Artery Pressure in Mitral Stenosis: An Exercise Echocardiographic Study. Circulation 2000; 102: 2378-2384.Маколкин В.И. Приобретенные пороки сердца. 4-е издание. М: ГЭОТАР-Медиа 2008.Wood P. Diseases of the heart and circulation. Philadelphia, PA: JB Lippincott 1956.Haworth S.G., Hall S.M., Panja M. Peripheral pulmonary vascular and airway abnormalities in adolescents with rheumatic mitral stenosis. Int J Cardiol 1988; 18: 405-416.Струков А.И., Тепляков А.Т., Пекарский В.В. Микроциркуляция при ревматическом митральном стенозе (клинико-морфологическое исследование путем биопсии легких). Арх патол 1985; 1: 11-19.Rounds S., Cutaia M.I. Pulmonary hypertension: pathophysiology and clinical disorders. In: Textbook of pulmonary diseases. Eds. Baum G., Crapo J., Celli B., Karpinsky J. 6th ed. Philadelphia-New York 1998.Коноплева Л.Ф., Ревуцкий Е.Л., Шевчук С.Г. Спорные вопросы патогенеза легочной гипертонии при митральных пороках. Врач дело 1990; 10: 30-33.Caramurú L.H., Soares Rde P., Maeda N.Y. et al. Hypoxia and altered platelet behavior influence von Willebrand factor multimeric composition in secondary pulmonary hypertension. Clin Appl Thromb Hemost 2003; 9: 251-258.Budhiraja R., Tuder R.M., Hassoun P.M. Endothelial dysfunction in pulmonary hypertension. Circulation 2004; 109: 159-165.Christman B.W., McPherson C.D., Newman J.H. et al. An imbalance between the excretion of thromboxane and prostacyclin metabolites in pulmonary hypertension. N Engl J Med 1992; 9: 70-75.Walston A., Peter R., Maris I. et al. Clinical implications of pulmonary hypertension in mitral stenosis. Amer J Cardiol 1973; 32 (5): 650-655.Pietra G.G., Capron F., Stewart S. et al. Pathologic assessement of vasculopaties in pulmonary hypertension. J Am Coll Cardiol 2004; 43 (12): 25-32. 2004.Ergün K., Balbay Y., G. Thrombotic, fibrinolytic and proliferative activities of pulmonary vascular bed in secondary pulmonary hypertension. Anadolu Kardiyol Derg 2005; 5: 95-100.Braunwald E. Valvular Heart Disease. In: Heart Disease: a Textbook of Cardiovascular Medicine. E. Braunwald, D.P. Zipes, P. Libby (eds). 6th ed. Philadelphia: Saunders 2001.Sagie A., Freitas N., Padial L.R. et al. Doppler echocardiographic assessement of long-term progression of mitral stenosis in 103 patients: valve area and right heart disease. J Am Coll Cardiol 1996; 28: 472-479.Авдеев С.Н., Чучалин А.Г. Одышка: механизмы развития, оценка и лечение. Пособие для врачей. М 2002.Батыралиев Т.А., Махмутходжаев С.А., Першуков И.В. Легочная гипертензия и правожелудочковая недостаточность. Часть 1. Кардиология 2006; 2: 74-82.Митьков В.В., Сандриков В.А. Клиническое руководство по ультразвуковой диагностике. М: Видар 1998.Fisher M.R., Forfia P.R., Chamera E. et al. Accuracy of Doppler echocardiography in the hemodynamic assessement of pulmonary hypertension. Am J Resp Crit Care Med 2009; 179: 615-621.Терещенко С.Н., Демидова И.В., Александрия Л.Г. и др. Диастолическая дисфункция левого желудочка и ее роль в развитии хронической сердечной недостаточности. Сердеч недостат 2000; 2: 61-65.López-Candales A., Dohi K. et al. Right ventricular dyssynchrony in patients with pulmonary hypertension is associated with disease severity and functional class. Cardiovasc Ultrasound 2005; 3: 23.Rajagopalan N., Dohi K., Simon M.A. et al. Right ventricular dyssynchrony in heart failure: a tissue Doppler imaging study. J Card Fail 2006; 12: 263-267.Mannucci P.M. Von Willebrand Factor: A Marker of Endothelial Damage? Arterioscler Thromb Vasc Biol 1998; 18: 1359-1362.Goldsmith I., Kumar P., Carter P. et al. Atrial endocardial changes in mitral valve disease: a scanning electron microscopy study. Am Heart J 2000; 140: 777-784.Yetkin E., Erbay A.R., Turhan H. et al. Decreased platelet activation and endothelial dysfunction after percutaneous mitral balloon valvuloplasty. Int J Cardiol 2003; 91: 221-225.Yamamoto K., Ikeda U., Seino Y. et al. Coagulation activity is increased in the left atrium of patients with mitral stenosis. J Am Coll Cardiol 1995; 25: 107-112.Penny W.F., Weinstein M., Salzman E.W., Ware J.A. Correlation of circulating von Willebrand factor levels with cardiovascular hemodynamics. Circulation 1991; 83: 1630-1636.Жарова Е.А., Горбачева О.Н., Насонов Е.Л. и др. Эндотелин. Физиологическая активность. Роль в сердечно-сосудистой патологии. Тер арх 1990; 8: 140-143.Krämer B.K., Ittner K.P., Beyer M.E. et al. Circulatory and myocardial effects of endothelin. J Mol Med 1997; 75 (11-12): 886-890.Snopek G., Pogorzelska H., Korewicki J. Influence of valve replacement on plasma endothelin-1 level in mitral stenosis. J Heart Valve Dis 2000; 9: 82-87.von Harsdorf R., Lang R., Fullerton M. et al. Right atrial dilatation increases inositol-(1,4,5)trisphosphate accumulation. Implications for the control of atrial natriuretic peptide release. FEBS Lett 1988; 233: 201-205.Stewart J., O'Dea D., ShapiroG. et al. Atrial compliance determines the nature of passive atrial stretch and plasma atrial natriuretic factor in the conscious dog. Cardiovasc Res 1991; 25: 784-792.Бугримова М.А., Савина Н.М., Ваниева О.С., Сидоренко Б.А. Мозговой натрийуретический пептид как маркер и фактор прогноза при хронической сердечной недостаточности. Кардиология 2006; 1: 51-57.Clerico A., Emdin M. Diagnostic accuracy and prognostic relevance of the measurement of cardiac natriuretic peptides: a review. Clin Chem 2004; 50: 33-50.Cardarelli R., Lumicao T. B-type natriuretic peptide: a review of its diagnostic, prognostic and therapeutic monitoring value in heart failure for primary care physicians. J Am Board Fam Pract 2003; 16: 327-333.Collins S. Use of Nt-pro-BNP in the emergency department evaluation of shortness of breath: implications for clinical practice. Emergency Medicine Cardiac Research and education group 2005; 6: 1-11.Januzzi J. Natriuretic peptide testing: a window into the diagnosis and prognosis of heart failure. Cleveland. Clin J Med 2006; 73: 155-157.Adams K., Mathur V., Gheorgiade M. et al. B-type natriuretic peptide from bench to bedside. Am Heart J 2003; 145: 34-46.Андреев Д.А., Мазеркина И.А., Гитель Е.Н. и др. Изменения мозгового натрийуретического пептида при лечении декомпенсации хронической сердечной недостаточности. Креатив кардиол 2007; 1-2: 136-143.Tokgözoglu L., Can I., Korkusuz P. et al. Correlation of tissue selectin expression and hemodynamic parameters in rheumatic mitral valve disease. J Heart Valve Dis 2006;15:671-678.Tekin A., Tekin G., Sezgin A.T. et al. Rheumatic mitral valve stenosis is associated with impaired flow-mediated dilatation. Int J Cardiol 2008; 25: 410-412.Bonow R.O., Carabello B.A., Kanu C. et al. American College of Cardiology/American Heart Association Task Force on Practice Guidelines; Society of Cardiovascular Anesthesiologists; Society for Cardiovascular Angiography and Interventions; Society of Thoracic Surgeons, ACC/AHA 2006 guidelines for the management of patients with valvular heart disease: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (writing committee to revise the 1998 Guidelines for the Management of patients with valvular heart disease): developed in collaboration with the Society of Cardiovascular Anesthesiologists: endorsed by the Society for Cardiovascular Angiography and Interventions and the Society of Thoracic Surgeons. Circulation 2006; 114: 84-231.Национальные Рекомендации ВНОК и ОССН по диагностике и лечению ХСН (III пересмотр). Сердеч недостат 2010; 1: 3-62.Руководство по неишемической кардиологии. Под ред. Н.А. Шостак М: ГЭОТАР-Медиа 2009.Perez-Gomez F., Salvador A., Zumalde J. et al. Effect of antithrombotic therapy in patients with mitral stenosis and atrial fibrillation: a sub-analysis of NASPEAF randomized trial. Eur Heart J 2006; 27 (8): 960-967.Bonow R.O., Carabello B.A., Chatterjee K. et al.; American College of Cardiology/American Heart Association Task Force on Practice Guidelines. 2008 focused update incorporated into the ACC/AHA 2006 guidelines for the management of patients with valvular heart disease: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to revise the 1998 guidelines for the management of patients with valvular heart disease). Endorsed by the Society of Cardiovascular Anesthesiologists, Society for Cardiovascular Angiography and Interventions, and Society of Thoracic Surgeons. J Am Coll Cardiol 2008; 52 (13): e1-142.